Anoop Patel

Research Interests

My research lab focuses on using single-cell sequencing techniques to study intratumoral heterogeneity in malignant brain tumors. Intratumoral heterogeneity is the idea that individual cancer cells within a patient’s tumor are different and can respond differently to treatments. I also have an active interest in developing patient-specific models of disease where we can learn how an individual patient's tumor might respond differently than another. My ultimate goal is to further advance precision medicine approaches for malignant brain tumors, and ensure that patients are getting the right treatments for their specific tumors.

Education

• M.D. Harvard Medical School, 2009

Positions

• Associate Professor of Neurosurgery
• Associate Professor in Pathology
• Associate Professor of Biomedical Engineering
• Member of the Duke Cancer Institute

Courses Taught

• UPGEN 778F: University Program in Genetics and Genomics Biological Solutions Module VI
• EGR 393: Research Projects in Engineering
• BME 791: Graduate Independent Study

Publications

• Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, et al. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Sci Rep. 2025 Oct 23;15(1):37112.
• Zachem TJ, Sperber JE, Chen SF, Adil SM, Wissel BD, Chamberlin G, et al. Intraoperative brain tumor classification via laser-induced fluorescence spectroscopy and machine learning. J Neurosurg. 2025 Aug 1;143(2):313u201322.
• Murie C, Turkarslan S, Patel AP, Coffey DG, Becker PS, Baliga NS. Individualized dynamic risk assessment and treatment selection for multiple myeloma. Br J Cancer. 2025 Jun;132(10):922u201336.
• Mihalas AB, Arora S, Ou2019Connor SA, Feldman HM, Cucinotta CE, Mitchell K, et al. KAT5 regulates neurodevelopmental states associated with G0-like populations in glioblastoma. Nat Commun. 2025 May 9;16(1):4327.
• Isham DC, Sytsma TM, Patel AP, Ramaiah VK. Methadone Analgesia During Awake Craniotomy for a Patient With Chronic Pain on Buprenorphine: A Case Report. A A Pract. 2025 Apr 1;19(4):e01957.
• Bomsztyk K, Mar D, Denisenko O, Powell S, Vishnoi M, Yin Z, et al. Analysis of DNA Methylation in Gliomas: Assessment of Preanalytical Variables. Lab Invest. 2024 Dec;104(12):102160.
• Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, et al. A brave new framework for glioma drug development. Lancet Oncol. 2024 Oct;25(10):e512u20139.
• Park JH, Hothi P, de Lomana ALG, Pan M, Calder R, Turkarslan S, et al. Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells. Sci Adv. 2024 Jun 7;10(23):eadj7706.
• Liu M, Ji Z, Jain V, Smith VL, Hocke E, Patel AP, et al. Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche. Acta Neuropathol Commun. 2024 Apr 22;12(1):64.
• Nuechterlein N, Shelbourn A, Szulzewsky F, Arora S, Casad M, Pattwell S, et al. Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype. Genes Dev. 2024 Apr 17;38(5u20136):273u201388.
• Hardigan AA, Jackson JD, Patel AP. Surgical Management and Advances in the Treatment of Glioma. Semin Neurol. 2023 Dec;43(6):810u201324.
• Chartrand T, Dalley R, Close J, Goriounova NA, Lee BR, Mann R, et al. Morphoelectric and transcriptomic divergence of the layer 1 interneuron repertoire in human versus mouse neocortex. Science. 2023 Oct 13;382(6667):eadf0805.
• Lee BR, Dalley R, Miller JA, Chartrand T, Close J, Mann R, et al. Signature morphoelectric properties of diverse GABAergic interneurons in the human neocortex. Science. 2023 Oct 13;382(6667):eadf6484.
• Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, et al. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nat Med. 2023 Oct;29(10):2402u20135.
• Lerner EC, Woroniecka KI, Du2019Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, et al. CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer. 2023 Sep;4(9):1258u201372.
• Mitchell K, Sprowls SA, Arora S, Shakya S, Silver DJ, Goins CM, et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. Genes Dev. 2023 Feb 1;37(3u20134):86u2013102.
• Park JH, Feroze AH, Emerson SN, Mihalas AB, Keene CD, Cimino PJ, et al. A single-cell based precision medicine approach using glioblastoma patient-specific models. NPJ Precis Oncol. 2022 Aug 8;6(1):55.
• Rajesh AE, Rubinstein JT, Ferreira M, Patel AP, Bly RA, Kohlberg GD. Automated objective surgical planning for lateral skull base tumors. Int J Comput Assist Radiol Surg. 2022 Mar;17(3):427u201336.
• Kalmbach BE, Hodge RD, Jorstad NL, Owen S, de Frates R, Yanny AM, et al. Signature morpho-electric, transcriptomic, and dendritic properties of human layer 5 neocortical pyramidal neurons. Neuron. 2021 Sep 15;109(18):2914-2927.e5.
• Park JH, de Lomana ALG, Marzese DM, Juarez T, Feroze A, Hothi P, et al. A systems approach to brain tumor treatment. Cancers. 2021 Jul 1;13(13).
• Wu SJ, Furlan SN, Mihalas AB, Kaya-Okur HS, Feroze AH, Emerson SN, et al. Single-cell CUT&Tag analysis of chromatin modifications in differentiation and tumor progression. Nat Biotechnol. 2021 Jul;39(7):819u201324.
• Ou2019Connor SA, Feldman HM, Arora S, Hoellerbauer P, Toledo CM, Corrin P, et al. Neural G0: a quiescent-like state found in neuroepithelial-derived cells and glioma. Mol Syst Biol. 2021 Jun;17(6):e9522.
• Tawil N, Bassawon R, Meehan B, Nehme A, Montermini L, Gayden T, et al. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv. 2021 Mar 23;5(6):1682u201394.
• Gutschenritter T, Venur VA, Combs SE, Vellayappan B, Patel AP, Foote M, et al. The judicious use of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy in the management of large brain metastases. Cancers. 2021 Jan 1;13(1):1u201315.
• Sekhar LN, Juric-Sekhar G, Qazi Z, Patel A, McGrath LB, Pridgeon J, et al. The Future of Skull Base Surgery: A View Through Tinted Glasses. World Neurosurg. 2020 Oct;142:29u201342.
• Ene CI, Kreuser SA, Jung M, Zhang H, Arora S, White Moyes K, et al. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Neuro Oncol. 2020 May 15;22(5):639u201351.
• Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 Aug 8;178(4):835-849.e21.
• Chiarelli PA, Patel AP, Lee A, Chandra SR, Sekhar LN. Sternocleidomastoid Encephalomyosynangiosis for Treatment-Resistant Moyamoya Disease. Oper Neurosurg. 2019 Jul 1;17(1):E23u20138.
• GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459u201380.
• Zeeshan Q, Patel A, Cheng C-Y, Zhao N-H, Barber J, Ghodke BV, et al. Resection of Meningiomas Involving Major Dural Venous Sinuses: Classification, Technique, and Long-Term Results. World Neurosurg. 2019 May;125:e521u201336.
• GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Apr;18(4):376u201393.
• Sekhar LN, Patel AP. Foreword. 2019.
• Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018 Sep 4;9(1):3588.
• Stapleton CJ, Patel AP, Walcott BP, Torok CM, Koch MJ, Leslie-Mazwi TM, et al. Surgical management of superior petrosal sinus dural arteriovenous fistulae with dominant internal carotid artery supply. Interv Neuroradiol. 2018 Jun;24(3):331u20138.
• Young CC, Hanak BW, Patel AP, Sekhar LN. Rapid Intraoperative in Situ Synthetic Cranioplasty. World Neurosurg. 2018 Apr;112:161u20135.
• Patel AP. High-Grade Gliomas. In: Principles of Neurological Surgery. 2018. p. 580-585.e2.
• Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017 Dec 14;171(7):1611-1624.e24.
• Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 Mar 31;355(6332).
• Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, et al. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell. 2017 Feb 2;20(2):233-246.e7.
• Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016 Nov 10;539(7628):309u201313.
• Nigim F, Cavanaugh J, Patel AP, Curry WT, Esaki S-I, Kasper EM, et al. Targeting Hypoxia-Inducible Factor 1u03b1 in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol. 2015 Jul;74(7):710u201322.
• Walcott BP, Patel AP, Stapleton CJ, Trivedi RA, Young AMH, Ogilvy CS. Multiplexed protein profiling after aneurysmal subarachnoid hemorrhage: characterization of differential expression patterns in cerebral vasospasm. J Clin Neurosci. 2014 Dec;21(12):2135u20139.
• Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvu00e0 ML, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014 Nov 10;26(5):668u201381.
• Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20;344(6190):1396u2013401.
• Suvu00e0 ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014 Apr 24;157(3):580u201394.
• Venteicher AS, Walcott BP, Sheth SA, Snuderl M, Patel AP, Curry WT, et al. Clinical features of brain metastasis from salivary gland tumors. J Clin Neurosci. 2013 Nov;20(11):1533u20137.
• Rheinbay E, Suvu00e0 ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013 May 30;3(5):1567u201379.
• Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, et al. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012 Sep;71(3):741u20138.
• Wakimoto H, Mohapatra G, Kanai R, Curry WT, Yip S, Nitta M, et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012 Feb;14(2):132u201344.
• Patel AP, Amin-Hanjani S, Ogilvy CS. Surgical Management of Cavernous Malformations of the Nervous System. In: Schmidek and Sweet Operative Neurosurgical Techniques Indications Methods and Results Sixth Edition. 2012. p. 977u201393.